CHALFONT ST GILES, England & SOLNA, Sweden--(BUSINESS WIRE)--GE Healthcare signed an agreement with Affibody AB (“Affibody”) to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year. Future clinical trials will investigate the confirmation of Her2 status in patients with breast cancer recurrence, to determine if Her 2 status changes over time, monitor therapy of patients with metastatic breast cancer receiving anti-Her2 treatments, and help resolve indeterminate Her2 tests. These studies, if positive, could ultimately pave the way for better targeting of anti-Her2 therapies to those patients most likely to benefit.
